D.A. Davidson & Co. Bluebird Bio, Inc. Transaction History

D.A. Davidson & Co.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$75.84 - $105.21 $106,176 - $147,294	-1,400 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$64.44 - $104.11 $90,216 - $145,754	1,400 New	1,400 $220,000
Q3 2018 Nov 13, 2018	SELL	$88.86 - $117.49 $114,629 - $151,562	-1,290 Closed	0 $0
Q2 2018 Aug 02, 2018	BUY	$99.64 - $127.59 $4,982 - $6,379	50 Added 4.03%	1,290 $202,000
Q1 2018 May 04, 2018	BUY	$105.8 - $150.94 $4,232 - $6,037	40 Added 3.33%	1,240 $212,000
Q4 2017 Feb 08, 2018	BUY	$81.25 - $130.7 $97,500 - $156,840	1,200 New	1,200 $214,000
Q3 2017 Nov 08, 2017	SELL	$57.74 - $91.42 $60,627 - $95,991	-1,050 Closed	0 $0
Q2 2017 Aug 11, 2017	BUY	N/A	1,050	1,050 $0

112

61.5M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $485M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.